Search

Search Results

• SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP

  Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini

  e2024020

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.020

  1054

  PDF: 1230

  HTML: 101

• HIV-ASSOCIATED VENOUS THROMBOEMBOLISM

  Michele Bibas, Gianluigi Biava, Andrea Antinori

  e2011030

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.030

  3872

  PDF: 1473

  HTML: 8513

• EPIDEMIOLOGY OF ACTIVATED PROTEIN C RESISTANCE AND FACTOR V LEIDEN MUTATION IN THE MEDITERRANEAN REGION

  Mehrez Mehrez M. Jadaon

  e2011037

  2011-09-08

  https://doi.org/10.4084/mjhid.2011.037

  3110

  PDF: 805

  HTML: 12902

• EPIDEMIOLOGY OF PROTHROMBIN G20210A MUTATION IN THE MEDITERRANEAN REGION

  Mehrez M. Jadaon

  e2011054

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.054

  2688

  PDF: 1127

  HTML: 2796

• Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis

  Alessandro Laganà, Giovanni Manfredi Assanto, Mauro Passucci, Cristina Santoro, Antonio Chistolini

  e2024047

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.047

  1163

  PDF: 982

  HTML: 92

• ANTITHROMBOTIC PROPHYLAXIS IN THE MIDDLE EAST

  Samir Arnaout, Hanady R. Samaha, Julien Succar, Imad Bou-Akl, Khaled M. Musallam, Ali T. Taher

  e2011023

  2011-05-23

  https://doi.org/10.4084/mjhid.2011.023

  1980

  PDF: 863

  HTML: 1349

• Direct oral anticoagulants (DOACs) in the onco-hematologic patients

  Mario Biglietto, Silvio Ligia, Alessandro Laganà, Giovanni Manfredi Assanto, Martina Gherardini, Erminia Baldacci, Cristina Santoro, Antonio Chistolini

  e2025022

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.022

  1008

  PDF: 979

  HTML: 102

• CURRENT ISSUES AND OPTIONS FOR HORMONAL CONTRACEPTION IN ADOLESCENTS AND YOUNG ADULT WOMEN WITH SICKLE CELL DISEASE: AN UPDATE FOR HEALTH CARE PROFESSIONALS Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease

  Vincenzo De Sanctis

  e2020032

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.032

  2156

  PDF: 1414

  HTML: 706

• DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA

  alessandra serrao, benedetta lucani, davide mansour, antonietta ferretti, erminia baldacci, cristina santoro, robin foà, antonio chistolini

  e2019044

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.044

  1939

  PDF: 1500

  HTML: 442

• Is laboratory monitoring useful in DOACs management?

  Mario Biglietto, Rosaria Mormile, Matteo Totaro, Maria Laura Bisegna, Cristina Santoro, Antonio Chistolini

  e2025019

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.019

  835

  PDF: 800

  HTML: 108

• BASELINE THROMBIN GENERATION TEST DOES NOT PREDICT THROMBOTIC EVENTS IN ACUTE LEUKEMIA: A MONOCENTRIC PROSPECTIVE STUDY

  Mario Biglietto, Rosaria Mormile, Maria Laura Bisegna, Alessandro Laganà, Anna Laura Faccini, Andrea Papa, Erminia Baldacci, Cristina Santoro, Maria Stefania De Propris, Antonio Chistolini

  e2025076

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.076

  393

  PDF: 183

  Html: 45

• INCREASED VASOOCCLUSIVE CRISIS IN “O” BLOOD GROUP SICKLE CELL DISEASE PATIENTS: ASSOCIATION WITH UNDERLYING THROMBOSPONDIN LEVELS.

  M. Al Huneini, Anil Pathare

  e2017028

  2017-04-20

  https://doi.org/10.4084/mjhid.2017.028

  2055

  PDF: 916

  HTML: 1365

• REVIEW AND RECOMMENDATIONS ON MANAGEMENT OF ADULT FEMALE THALASSEMIA PATIE?TS WITH HYPOGONADISM BASED ON LITERATURE REVIEW AND EXPERIENCE OF ICET-A NETWORK SPECIALISTS

  Vincenzo De Sanctis

  e2017001

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.001

  6093

  PDF: 1429

  HTML: 1935

• Protein S deficiency with recurrent thromboembolism in a patient with hemoglobin H disease following splenectomy

  Kun Yang

  e2024017

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.017

  579

  PDF: 1053

  HTML: 86

• SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology

  Firas Kreidieh, Sally Temraz

  e2020078

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.078

  1058

  PDF: 960

  HTML: 327

• PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID

  Francesco Rodeghiero

  e2021032

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.032

  2484

  PDF: 922

  HTML: 527

• REAL WORLD DATA ON CHARACTERISTICS AND MANAGEMENT OF COMMUNITY PATIENTS RECEIVING ANTICOAGULATION THERAPY WHO PRESENTED WITH ACUTE BLEEDING TO THE EMERGENCY DEPARTMENT AT A REGIONAL AUSTRALIAN HOSPITAL: A PROSPECTIVE OBSERVATIONAL STUDY. Anticoagulation and bleeding ?

  Fayez Hanna, Annemarie Hyppa, Ajay Prakash, Usira Vithanarachchi, Hizb U Dawar, Zar Sanga, George Olabode, Hamish Crisp, Professor Alhossain A. Khalafallah

  e2021017

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.017

  1568

  PDF: 540

  HTML: 316

• IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA DECREASED BY THE INCREASED USE OF LOW-MOLECULAR-WEIGHT-HEPARIN?

  Fahad Al-Eidan

  e2015029

  2015-04-19

  https://doi.org/10.4084/mjhid.2015.029

  1658

  PDF: 818

  HTML: 1467

• IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES

  Silvia Maria Trisolini, Alessandro Laganà, Saveria Capria

  e2024060

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.060

  2076

  PDF: 1796

  HTML: 157

• SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM

  Zohreh Rahimi, Abbas Parsian

  e2011024

  2011-05-23

  https://doi.org/10.4084/mjhid.2011.024

  2236

  PDF: 870

  HTML: 2092

• THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis

  Nicola Semeraro, Prof. Mario Colucci

  e2021045

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.045

  1958

  PDF: 811

  HTML: 220

• CLINICAL CARE PATHWAY AND MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A MODIFIED DELPHI CONSENSUS FROM SAUDI ARABIA AND UAE

  Abdulrahman Al Raizah, Fakhr Alayoubi, Galal Hassan Abdelnaby, Hazzaa Alzahrani, Majid Farraj Bakheet, Mohammed A Alskaini, Rasha Buhumaid, Sameer Al Awadhi, Sara Nooruddin Kazim, Thiagarajan Jaiganesh, Zohair Al Asiri

  e2024038

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.038

  2569

  PDF: 1177

  HTML: 105

• COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.

  Federico Mercolini, Simone Cesaro

  e2022009

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.009

  2261

  PDF: 933

  HTML: 301

• HOW THE HEMOSTASIS LABORATORY CAN HELP CLINICIANS TO MANAGE PATIENTS ON ORAL ANTICOAGULANTS

  Armando Tripodi

  e2024027

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.027

  996

  PDF: 1345

  HTML: 129

• BACTERIAL INFECTIONS FOLLOWING SPLENECTOMY FOR MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES

  Giuseppe Leone, Eligio Pizzigallo

  e2015057

  2015-10-12

  https://doi.org/10.4084/mjhid.2015.057

  4854

  PDF: 1964

  HTML: 8316